Novartis has recently emphasized its dedication to molecular glue strategies, a significant move in the biotech sector.
This announcement comes at a time when drug costs for seniors are reportedly increasing sharply, raising concerns about accessibility.
Additionally, developments in leukemia treatments, particularly from companies like Enliven, are also making headlines in the industry.